We Are Providing Diagnostic &
Sapphire Biotech’s proprietary research intends to find new ways to diagnose and treat cancer as well as other conditions through laboratory-derived oncological therapeutics.
Sapphire’s clinical therapeutic research focuses around an enzyme called “QSOX1” where the company hopes to bring a novel oncology drug to market
Dedicated to Changing Lives Through Research
Sapphire Biotech has identified a unique enzyme, Quiescin Sulfhydryl Oxidase 1 (QSOX1), which is elevated in cancer patients and can be detected earlier than circulating tumor cells. The company’s development of QSOX1 as a unique cancer biomarker has led it to important discoveries based on testing hundreds of human samples. Sapphire’s lead compound has been tested in animal studies has shown to significantly reduce tumors by two-thirds in under 20 days.
Global Demand and Growing Market Potential
With the oversight and expertise of internationally-recognized scientists and medical experts, Sapphire Biotech not only has great potential to help hundreds of millions of cancer patients throughout the U.S., but also become a strategic asset for its investors. The global cancer therapy market is experiencing a strong growth pattern with a CAGR over the next four years of 8.37% and 90% of cancer patients dying from metastatic cancer. Sapphire’s team has developed never-before-seen and proven compounds to combat metastatic cancer.
2018 Global Cancer Therapy Market Value
Estimated Global Cancer Therapy Market Value by 2024
Of cancer deaths are caused by metastatic cancer
Sapphire Biotech Files for Patent Protection and Tests 200 Bladder Cancer Patient Samples to Validate its Unique Biomarker to Detect Cancer
Sapphire began testing 200 bladder cancer patient samples to test for the presence of QSOX1-related biomarkers. Utilizing Sapphire’s proprietary antibodies to test the bladder cancer samples, Sapphire developed a prototype rapid diagnostic test that measures levels of...
Sapphire Biotech, Inc. is Formed to Develop Novel Therapeutic Approaches for the Treatment of Cancer Metastasis
Sapphire Biotech’s technology was formed for the purpose of developing novel therapeutic approaches for the treatment of cancer metastasis. Sapphire has identified a novel compound, SBI-183, that selectively targets QSOX1, an enzyme important for tumor cell growth,...
Sapphire Biotech, Inc.
6191 Cornerstone Court, E., Suite 114
San Diego, CA 92121